Serum visfatin and omentin levels in slow coronary flow

Ucgun, Taner; Başar, Cengiz; Memişoğulları, Ramazan; Demırın, Hilmi; Türker, Yasin; Aslantaş, Yusuf

doi:10.1016/j.repc.2014.04.007

Cited by 15 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The difference between the two groups was signi cant (P = 0.003). Studies have shown that reducing the level of omentin-1 in serum leads to slow coronary blood ow, and, except for acute coronary syndrome, the level of plasma omentin-1 in patients with stable coronary heart disease is lower than that in normal controls [22,7]. Serum omentin-1 levels have been shown to decrease at the onset of acute coronary syndrome and then increase after 6 months of follow-up.…”

Section: Discussionmentioning

confidence: 99%

Relationship between omentin-1 levels in patients with coronary artery disease and healthy controls: A systematic review and meta-analysis

Tongxia

CHEN

2023

Preprint

View full text Add to dashboard Cite

Background Omentin-1 is associated with diseases such as obesity, hypertension, diabetes, and coronary heart disease, as well as a range of metabolisms. This paper aims to describe the role of omentin-1 in patients with coronary artery disease (CAD).Method We performed a systematic review and meta-analysis of omentin-1 levels in patients with CAD compared to those in healthy individuals. We searched PubMed, Embase, and Cochrane Library from database inception to July 2022. The data extracted included the author, publication year, country, study design, sample size, sex, age, body mass index, sample source, and outcomes including levels of omentin-1 and their relationship with CAD. All data were analyzed using STATA Statistical Software, version 15.1 (StataCorp, College Station, TX, USA). For continuous variables, standardized mean difference (SMD), and mean difference (95% confidence interval [CI]) the combined effect size was used, and for risk factor assessment, the odds ratio (OR; 95% CI) was used. Both I2 and Q tests were used to evaluate heterogeneity.Results Twelve case-control studies were included in the meta-analysis. The sample size of the patients was 2034, including 1205 patients with CAD and 829 healthy controls. There were 10 studies that compared omentin-1 levels in patients with CAD to those in healthy people. The pooled results showed that the level of omentin-1 in patients with CAD was significantly lower than that in healthy people (SMD = -1.56, 95% CI: -2.00 to -1.13, P = 0.000). Five studies reported an association between omentin-1 levels and CAD. The pooled results suggested that elevated omentin-1 levels were associated with reduced incidence of CAD (OR = 0.95, 95% CI: 0.91 to 0.99).Conclusion The pooled results showed that the level of omentin-1 in patients with CAD was significantly lower than that in healthy people and suggested that elevated omentin-1 levels are associated with reduced incidence of CAD.

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship between omentin-1 levels in patients with coronary artery disease and healthy controls: A systematic review and meta-analysis

Tongxia

CHEN

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…It has also been reported that myocardial fibrosis promotes various conduction abnormalities and causes malignant VA to occur [ 29 – 32 ]. Furthermore, considering its key role in unstable plaques, higher circulating visfatin concentrations have been observed in patients with slow coronary flow [ 33 ], which contributes to malignant VA. Notably, visfatin levels also differed statistically between patients with benign VA and control patients without SHD.…”

Section: Discussionmentioning

confidence: 99%

Serum visfatin concentrations are positively associated with ventricular arrhythmias: a single-center preliminary study

Shen

Zhang

Guo

et al. 2022

Turkish Journal of Medical Sciences

View full text Add to dashboard Cite

Background/aim Visfatin has been reported to be closely related to cardiovascular diseases associated with inflammation, but the correlation between visfatin and ventricular arrhythmia (VA) has not been discussed yet. The study aims to explore the association between serum visfatin concentrations and VA in patients. Materials and methods Sixty-seven hospitalized patients diagnosed with VA and 131 control subjects were enrolled in this cross-sectional study between May 20, 2017 and November 8, 2019. Classification of VA types was based on the presence of structural heart disease (SHD). The patients’ blood samples were collected to examine their serum levels of visfatin. Results were analyzed using analysis of variance and t-test. Furthermore, binary logistic regression analysis was used to validate whether elevated visfatin was independently associated with VA. Results Compared with the controls (mean age, 64.2 ± 13.2 years; 71% of men), the patients with VA (68.2 ± 11.6 years, 58%) had higher serum levels of visfatin (1.80 ± 0.47 ng/mL versus 1.48 ± 0.41 ng/mL; p <0.001). After further grouping patients according to the presence of SHD, the serum levels of VA patients with SHD were the highest. Moreover, binary logistic regression analysis identified age (OR = 1.043; 95% CI, 1.015–1.072, p = 0.003), history of stroke (OR = 2.065; 95% CI, 1.450–5.696, p = 0.005), hsCRP (>10 mg/L) (OR = 4.123; 95% CI, 1.888–9.001, p < 0.001), and elevated visfatin level (>1.40 ng/L) (OR = 3.126; 95% CI, 1.544–6.328, p = 0.002) as independent risk factors with VA. Conclusion Serum visfatin levels were significantly elevated in the patients with VA, and increased with the risk rating of VA.

show abstract

“…26 Studies detected an association between inflammatory markers and the SYNTAX score, and found a strong correlation between these markers and the extent of CAD. 7,27 The role of visfatin in the inflammatory process and in the maturation of vascular smooth muscle cells 28 can shed light on a possible effect of coronary atherosclerosis. Therefore, visfatin may act as a proinflammatory cytokine, play a role in chronic inflammation, and may contribute to the pathogenesis of atherosclerosis and CVD.…”

Section: Discussionmentioning

confidence: 99%

“…Visfatin may be related to endothelial function, which is indispensable for coronary circulation, and may be an indicator of an inflammatory event in the coronary arteries. 7 Many studies have investigated the relationship between inflammation markers and the extent of CAD. 8–10 In this study, we emphasized that inflammation involved with the severity and extent of coronary atherosclerosis might be related to serum visfatin level in patients with stable CAD.…”

Section: Introductionmentioning

confidence: 99%

Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris

Duman

Özyıldız

Bahçeci

et al. 2019

Therapeutic Advances in Cardiovascular Disease

View full text Add to dashboard Cite

Background: Visfatin is an adipokine that plays a role in the inflammatory process of atherosclerosis. This study aimed to investigate whether adipokine is associated with the extent of stable coronary artery disease (CAD). Methods: The study population included 110 patients who underwent elective coronary angiography (CAG) due to stable angina pectoris. The severity of CAD was assessed by the ‘Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX)’ score. We evaluated patients in two groups: group 1 with a SYNTAX score <22 (low) and group 2 with a SYNTAX score ⩾22 (intermediate to high). Results: Serum visfatin (8.6 ± 4.2 ng/ml versus 13.4 ± 5.2 ng/ml, p < 0.001) and serum C-reactive protein (CRP) levels [0.46 (0.25–0.77) mg/dl versus 0.71 (0.32–1.10) mg/dl, p < 0.001] were lower in group 1. A positive significant correlation was found between serum visfatin level and SYNTAX score ( r = 0.559, p < 0.001). In a multivariate logistic regression analysis, visfatin [odds ratio (OR) 1.22, 95% confidence interval (CI) 1.10–1.36; p < 0.001], CRP (OR 6.22, 95% CI 1.70–22.7; p = 0.006), and diabetes mellitus (OR 3.83, 95% CI 1.10–13.2; p = 0.034) were found to be independent predictors of SYNTAX score. Conclusions: Serum visfatin level was positively correlated with CAD severity in patients with high SYNTAX score. Serum visfatin level can be a useful biomarker for predicting high SYNTAX scores in patients with angina pectoris undergoing CAG.

show abstract

Serum visfatin and omentin levels in slow coronary flow

Abstract: Adipocytokines such as visfatin and omentin may play a role in the pathogenesis of coronary slow flow.

Cited by 15 publications

References 24 publications

Relationship between omentin-1 levels in patients with coronary artery disease and healthy controls: A systematic review and meta-analysis

Relationship between omentin-1 levels in patients with coronary artery disease and healthy controls: A systematic review and meta-analysis

Serum visfatin concentrations are positively associated with ventricular arrhythmias: a single-center preliminary study

Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris

Contact Info

Product

Resources

About